Illumina Ventures’ Post

Antibody Drug Conjugates (#ADCs) Keep Growing! Tubulis GmbH, a German ADC #biotech #startup, raises €128 million ($138.8 million) Series B2 financing to accelerate the clinical development of solid tumour-focused ADC pipeline. The financing round is co-led by EQT Life Sciences and Nextech Invest, with participation from current and new leading global biotechnology investors. According to MarketsandMarkets™’s report, the global ADCs market in terms of revenue was estimated to be worth $9.7 billion in 2023 and is poised to reach $19.8 billion by 2028, with a CAGR of 15.2% from 2023 to 2028. Other leading players in the global ADCs market include: - AbbVie/ ImmunoGen, Inc. - Adcendo - Adcentrx Therapeutics - Alentis Therapeutics - AstraZeneca/ Daiichi Sankyo, Inc. - BioNTech SE/ Duality Biologics - Bristol Myers Squibb - GSK - Innovent Biologics - Pfizer/ Seagen

🚀🔬 It’s time to take a look at the biggest private biotech investments of July 2024! 💰 Last month, the companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest investment rounds. 🎯 And, just as in June, oncology and central nervous system players attracted the biggest funding rounds overall. 🧠💉 📍Plus, in terms of location, North America and Europe also achieved the same amount of fundraising rounds as they did in June, with 15 and 11 respectively. 🌍💼 Read our latest article to find out more details! 🔍 https://lnkd.in/d4xze2x7 #biotech #investments #pharma #oncology #innovation #funding #biotech2024 #healthcare CatalYm GmbH | Scorpion Therapeutics | NGM Biopharmaceuticals | Myricx Bio | Asceneuron SA | Autobahn Therapeutics, Inc. | SciRhom | Confo Therapeutics | GRO Biosciences | AIRNA | SmartCella Holding AB | AusperBio | Rona Therapeutics | CellCentric | ReviR Therapeutics | LTZ Therapeutics

Recent Funding: Marea Therapeutics (SF) has emerged with $190 million and a mid-stage #cardiometabolic clinical program. Incubated by Third Rock Ventures, the #biotech will use the money to fund phase 2 activities for lead program MAR001, a monoclonal antibody (#mAb) designed to inhibit ANGPTL4, a protein highly expressed in body fat. Preclinical models found that MAR001 reduced triglycerides, remnant cholesterol and ectopic fat, while improving insulin sensitivity. The biotech plans to launch a phase 2b trial assessing MAR001 for #metabolic dysfunction in the beginning of next year. Iambic Therapeutics (San Diego) has now raised an oversubscribed $50 million extension round led by new investors Mubadala Capital and Exor Ventures. The new cash will be used to advance the biotech's #clinical and #preclinical pipeline. This includes IAM1363, a small molecule inhibitor designed to treat both wild-type and oncogenic HER2 mutants currently in phase 1/1b testing, as well as a preclinical dual CDK2/4 inhibitor designed to tackle treatment resistance in solid tumors. āshibio, Inc (Brisbane) exited stealth mode today with $40 million in seed and Series A financing to advance therapies for bone and connective tissue disorders. MPM BioImpact led the Series A round, with contributing funds from Agent Capital, YK Bioventures, and Mirae Asset Capital Life Science. Recent Layoffs:  eFFECTOR Therapeutics, Inc. (Solana Beach): The #oncology biotech has laid off staff as it plans to wind down. This includes eFFECTOR CEO Stephen Worland, Ph.D.; CFO Michael Byrnes; and CMO Douglas Warner, M.D., who all stopped serving in their positions at the end of last week. M&A, Deals, Partnerships: Belharra Therapeutics (San Mateo & San Diego), a next-generation #chemoproteomics company transforming small molecule drug discovery by illuminating binding pockets on elusive, high-value drug targets across the proteome, announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for #immunological diseases. FDA Approvals: Halozyme, Inc. (San Diego) announced that argenx received U.S. FDA approval for VYVGART® Hytrulo co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (#CIDP). Adicet Bio, Inc (Redwood City) announced that the U.S. FDA has cleared the Company’s IND application to evaluate ADI-270, an armored allogeneic “off-the-shelf” gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70+ #cancers, for the treatment of relapsed/refractory renal cell #carcinoma (RCC). 4D Molecular Therapeutics (SF) announced U.S. FDA clearance of the IND for 4D-175, an R100 vector-based intravitreal #genetic medicine, for the treatment of patients with geographic atrophy.

10/3/24: Syncona Limited : Resolution Therapeutics Raises £63.5 Million in Series B Financing | Appoints New Chair Use of proceeds from the Series B financing will support the clinical entry and development of RTX001, with a Phase I/II trial expected to start in Q4 CY2024. Following this financing, Resolution Therapeutics is funded to deliver data from this trial, anticipated in CY2026, a key value inflection point with the potential to drive significant NAV growth for Syncona. Proceeds will also be used to develop the company’s manufacturing platform, expand the pre-clinical pipeline, and further strengthen the management team, following several key recent appointments, including Dr Amir Hefni as CEO, Simon Ramsden as CFO and Dr Clifford A. Brass as CMO. Read the full scoop at https://lnkd.in/eG_3gs6D

𝗕𝗼𝘂𝗻𝗱𝗹𝗲𝘀𝘀 𝗕𝗶𝗼 𝗯𝗼𝗹𝗱𝗹𝘆 𝗴𝗼𝗲𝘀 𝗽𝘂𝗯𝗹𝗶𝗰 𝘄𝗶𝘁𝗵 $𝟭𝟬𝟬𝗠 𝗜𝗣𝗢 Boundless Bio is bringing in $100 million from its IPO as the precision oncology company becomes the latest biotech to go public in 2024. The company has priced its 6.25 million shares at $16 apiece, squarely in the middle of the $15 to $17 range the biotech set out in a Securities and Exchange Commission filing last week. Those gross proceeds could swell to $115 million if underwriters take up the offer of buying an additional 937,500 shares at the same price. Boundless' stock is due to start trading on the Nasdaq Global Select Market this morning under the ticker “BOLD.” When ranked against the crop of biotech IPOs that emerged in the opening weeks of the year, Boundless sits toward the bottom of the scale. So far, preclinical gene editing company Metagenomi is the only traditional biotech to have brought in less than $100 million, while CG Oncology has retained the top spot for 2024 so far with its eyebrow-raising $380 million IPO in January. Boundless isn’t the only biotech IPO set for spring. Contineum Therapeutics also filed paperwork this month to raise money for phase 2 trials of its lead prospect and a Johnson & Johnson-partnered molecule. https://lnkd.in/eRBQpgwg

InduPro Announces $85M Series A Financing https://lnkd.in/dHZJ3itc InduPro, Inc. , a biotechnology company defining protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced an $85 million Series A financing co-led by The Column Group and Vida Ventures with participation from investors, including MRL Ventures Fund (the therapeutics-focused venture fund of Merck & Co, Inc.), Emerson Collective and Euclidean Capital. The financing will support the advancement of the first expected clinical product candidate targeting cancer tissue based on the proximity of co-targeted pairs, from preclinical development to an expected IND filing in Q4 2025 for a Phase 1 clinical trial. It will also fuel a pipeline of novel bispecific antibodies and antibody drug conjugates (ADCs) that utilizes protein proximity for identification of novel tumor selective target pairings. Prakash Raman, Ph.D. joins as Chief Executive Officer of InduPro with more than two decades of biopharmaceutical business development and executive leadership experience, blending his… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

UNP Scores $32M for AI-Powered Macrocycle Therapeutics - HIT Consultant #UNP Scores $32M for AI-Powered Macrocycle Therapeutics #Summary: UNP, a healthcare technology company, has raised $32 million in funding for its AI-powered macrocycle therapeutics. The company aims to develop novel treatments for diseases that are currently difficult to treat. The funding will be used to advance the company's drug discovery platform and accelerate the development of its pipeline. UNP's technology combines artificial intelligence and machine learning to design and optimize macrocycles, which are large, complex molecules that can interact with disease targets. The company's approach has the potential to revolutionize drug discovery and lead to the development of more effective therapies. #Introduction: UNP, a healthcare technology company, has secured $32 million in funding ai.mediformatica.com #platform #funding #oncology #biotech #design #globalhealth #health #healthinnovation #innovation #medical #merckglobalhealthinnovationfund #seriesa #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3tp5PyH)

💲Notable RNA deals in March and April 💲 These deals underscore the significance of RNA therapeutics and the delivery systems that ensure their precise targeting and efficacy. Headlined by the acquisition of Cardior Pharmaceuticals by Novo Nordisk for $1.1b USD. Cardior Pharmaceutical technology specializes in targeting abnormal levels of microRNA. Capstan Therapeutics raised an impressive $175m in their oversubscribed Series B. Capstan Therapeutics is looking to advance their CAR-T cell candidate and their targeted LNP pipelines. Regulus Therapeutics recently announced an oversubscribed $100m private placement of equity. They are focused on their pipeline candidates which target microRNAs. Orgenesis Inc. secured a $2.3m private investment and is expected to secure further payments. Orgenesis is a biotech focused on cell and gene therapies, aiming to provide affordable healthcare to patients. ----- Century Therapeutics, Inc raised $60m in private investments and used these funds to acquire Clade Therapeutics. With this move, Century adds to their allogeneic cell therapies. TuHURA Biosciences, Inc. received $31m subscribed financing and have entered into a definitive merger agreement with Kintara Therapeutics, Inc. NASDAQ: KTRA. GenEditBio Limited recently announced their $10m USD Pre-A+ funding round, their third funding round since 2021. The additional funds will be used to further their genome-editing technology platforms, e.g. LNPs and ePDVs. ARCA biopharma and Oruka Therapeutics announced their merger agreement earlier this month. They will look to advance Oruka's pipeline of potentially best-in-class biologics for the treatment of chronic skin diseases. ----- Deals pulled from Beacon Intelligence database. 🌟 Enjoying my content? Repost and follow Michael Hai Luu Nguyen, Ph.D. & Helix Biotech, Inc. for more! 🌟 #RNA #mRNA #RNAtherapeutics #LNPs #LNP #Helixbiotech #investors #deals #funding #biotech #pharma

Merger & Acquisition Life Science / Healthcare 2023 Landscape Review Already this year we’ve seen Sanofi enter an agreement to acquire all outstanding shares of Inhibrx, Inc., as well as Johnson & Johnson’s recent acquisition of Ambrx Biopharma. 🔍 A quick review of Beacon Deals & Companies showed we identified 86 M&A deals last year 🔍 So, here’s one from every month … 🤝December: Bristol Myers Squibb Announced Definitive Merger Agreement to Acquire RayzeBio 🤝November: Selecta Biosciences Announces Merger with Cartesian Therapeutics 🤝October: Kyowa Kirin, Inc.- U.S. to Acquire Orchard Therapeutics 🤝September: Renovaro Biosciences Inc. and GEDiCube Sign Definitive Agreement to Combine 🤝August: Serina Therapeutics, Inc. and AgeX Therapeutics, Inc. Enter into Merger Agreement 🤝July: Biogen to Acquire Reata Pharmaceuticals, Inc. 🤝June: Talaris Therapeutics and Tourmaline Bio Entered into Merger Agreement 🤝May: Pyxis Oncology to Acquire Apexigen 🤝April: NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV 🤝March: Flamingo Therapeutics Signed a Definitive Merger Agreement with Dynacure 🤝February: Kite Pharma Completed the Acquisition of Tmunity Therapeutics Incorporated 🤝January: Leap Therapeutics Acquires Flame Biosciences If you’re interested in learning more about how Beacon tracks the company and deal data in the Cell Therapy, Gene Therapy, RNA, ADC, Bispecific, Immune Tolerance, Checkpoint, Cytokine, DDR, TPD, Microbiome, Cancer Vaccine, or Oncolytic Virus landscapes drop me a message. #drugdevelopment #pharma #MnA #biotech

🕺 DISCO Pharmaceuticals GmbH launches with €20 Million Seed Financing! 🚀 🔬 Based out of Germany & Switzerland, DISCO are unravelling the surfaceome of cancer cells on a large scale, uncovering novel targets and pioneering the development of ground-breaking, first-in-class drugs. 💸 The financing is backed by a prominent investor syndicate, which includes Panakes Partners, M Ventures , AbbVie Ventures, with Sofinnova Partners spearheading the financing. 🗣 "𝘞𝘦 𝘣𝘦𝘭𝘪𝘦𝘷𝘦 𝘵𝘩𝘢𝘵 𝘰𝘶𝘳 𝘴𝘶𝘳𝘧𝘢𝘤𝘦𝘰𝘮𝘦 𝘥𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘪𝘴 𝘵𝘳𝘶𝘭𝘺 𝘥𝘪𝘴𝘳𝘶𝘱𝘵𝘪𝘷𝘦 𝘢𝘯𝘥 𝘸𝘪𝘭𝘭 𝘵𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮 𝘰𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘰𝘱𝘵𝘪𝘰𝘯𝘴 𝘢𝘯𝘥 𝘶𝘭𝘵𝘪𝘮𝘢𝘵𝘦𝘭𝘺 𝘪𝘮𝘱𝘳𝘰𝘷𝘦 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴." Roman Thomas ▶ 2024 has kicked off in excellent fashion, long may the good news continue! Check out the link posted below to learn more about DISCO Pharmaceuticals GmbH - congratulations to all involved. #biotech #drugdiscovery #proteomics #surfaceome